H
eart failure (HF) is a complex clinical syndrome characterized by fatigue, dyspnea, and exercise intolerance attributable to impaired cardiac function and associated pathophysiologic consequences. The current treatment paradigm in HF targets relief from congestion and inhibition of neurohormonal activation. Although this approach is undoubtedly valuable, HF remains a leading cause of hospitalization, readmission after discharge predicts a poor prognosis and diminished quality of life, 1 and the number is expected to rise. 2 These data suggest that the current standard of care fails to interrupt one or more key mechanisms of disease progression.
The evidence of heightened systemic inflammation in heart disease is overwhelming. 3, 4 However, there are currently no anti-inflammatory strategies routinely used for the treatment of HF. Recently completed proof-ofconcept studies have tested the feasibility of IL-1 (interleukin-1) blockade with anakinra (Kineret; Swedish Orphan Biovitrum, Stockholm, Sweden) for 14 days in patients with stable systolic HF, 5 stable diastolic HF, 6 and acute decompensated HF 7 , suggesting a favorable safety and tolerability profile, a significant reduction in C-reactive protein (CRP) levels, and a significant improvement in peak oxygen consumption (Vo 2 ). 5, 6 The purpose of the current study was to determine whether IL-1 blockade with anakinra would improve aerobic exercise capacity in patients with recently decompensated systolic HF.
METHODS

Study Design
The study design of the REDHART (REcently Decompensated Heart failure Anakinra Response Trial) has been previously presented. 8 Approval was obtained from the Virginia Commonwealth University Institutional Review Board, and all participants provided written informed consent. After an initial screening and evaluation, patients underwent a cardiopulmonary exercise test (CPX), a transthoracic echocardio-Doppler study, testing for biomarkers, at baseline and at 2, 4, 12, and 24 weeks. 8 Patients were randomized in a 1:1:1 ratio to 1 of 3 treatment arms exploring 2 different durations of anakinra treatment: (1) anakinra 100 mg daily for 2 weeks, followed by placebo (equal volume of 0.67 mL) daily for the remaining 10 weeks; (2) anakinra 100 mg daily for 12 weeks; or (3) placebo daily for 12 weeks ( Figure I in the Data Supplement). The anakinra dosing follows the approved regimen for rheumatoid arthritis and is the same regimen used in the 2-week proof-of-concept studies. 5, 6 Screening and Enrollment Consecutive patients were screened for enrollment during the initial hospital admission or within 2 weeks of discharge. The inclusion and exclusion criteria are presented in Table I in the Data Supplement and previously. 8 Briefly, patients were considered for enrollment if they had been admitted with a diagnosis of acute (or acute-on-chronic) systolic HF based on symptoms, signs, biomarkers, or noninvasive or invasive measures of elevated cardiac filling pressures and reduced left ventricular ejection fraction (LVEF<50%). 8 Before enrollment, patients needed to be considered clinically stable and ready for hospital discharge, able and willing to follow study instruction and complete study tests, but with evidence of enhanced systemic inflammation, as shown by CRP plasma levels >2 mg/L (measured by high-sensitivity assay). Patients needed to be free of malignancy or systemic inflammatory illnesses.
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Randomization and Allocation Concealment
An independent investigator (G.B.-Z.) created a randomization sheet that was then provided to the Investigational Pharmacy in Richmond, Virginia. Anakinra or placebo (vehicle) were provided by SOBI (Stockholm, Sweden) in 0.67 mL syringes identifiable by lot number but otherwise indistinguishable. To further ensure concealment of group allocation, the investigators were blinded to all CRP levels throughout the study other than the screening level.
Data and Safety Monitoring Board
A Data and Safety Monitoring Board was formed according to the US Food and Drug Administration recommendations. 9 Table II in the Data Supplement shows the composition of the Data and Safety Monitoring Board.
Cardiopulmonary Exercise Testing
A supervised maximal aerobic exercise test was administered using a metabolic cart adapted to a treadmill using a conservative ramping treadmill protocol, as described. 5, 6, 8, 10 The peak respiratory exchange ratio was used to determine subject effort and a peak value ≥1.00 was considered a minimal acceptable threshold. 11, 12 Patients who interrupted the CPX
WHAT IS NEW?
• An enhanced inflammatory response is associated with a greater burden of symptoms and predicts worse outcomes in heart failure.
• We tested whether treatment with a specific intervention aimed at blocking IL-1 (interleukin-1) activity would improve exercise tolerance in patients with recently decompensated systolic heart failure.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Treatment with anakinra, a recombinant IL-1 receptor antagonist, was safe and well tolerated, and although it did not improve exercise tolerance after 2 weeks, an improvement was seen in those patients in whom anakinra was continued for 12 weeks.
• Further studies are warranted to explore IL-1 blockade as a novel therapeutic strategy in heart failure.
for reasons other than dyspnea (ie, ischemia, arrhythmias, and leg pain) were excluded and considered screen failures if occurring at the time of the baseline test or the first followup at 2 weeks or kept in the analysis of clinical event, but the results of the CPX were not considered for that visit. The deidentified data from each CPX were transferred to Dr Ross Arena, PhD, at the Core Lab at the University of Illinois at Chicago, Chicago, Illinois, for analysis.
Doppler Echocardiography
All subjects underwent a transthoracic Doppler echocardiogram before initiation of treatment and at each additional visit to measure left ventricular dimension and function, as previously described. 13, 14 All measurements occurred off-line at the end of the study by 2 separate operators blinded to group allocations. The average of the 2 measurements was used for measures differing ≤10%, whereas those with >10% were rereviewed and discussed to achieve consensus. We used the noninvasive hemodynamic monitor ccNexfin (BMEYE, Amsterdam, The Netherlands; and Edwards Lifesciences, Irvine, CA) 15 coupled with transthoracic echocardiography to calculate arterial elastance (E a ) and 16 end-systolic elastance (E es ), 17 and ventriculo-arterial coupling was defined as the E a /E es ratio (Data Supplement).
Laboratory Analysis and Biomarkers
Blood samples were used for a complete blood count with differential, comprehensive metabolic profile, and plasma levels of biomarkers (eg, high-sensitivity CRP, brain natriuretic peptide [BNP] , and inflammatory cytokines).
Quality-of-Life Assessments
All patients completed 2 different quality-of-life questionnaires at each visit: the Duke Activity Status Index (DASI) 18 and the Minnesota Living with Heart Failure (MLWHF). 19 These questionnaires were selected to explore different aspects of HF symptoms: a lower DASI score reflects impaired functional capacity, whereas a higher MLWHF score reflects greater symptom burden.
Clinical Events
A dedicated committee adjudicated all clinical events (Table III in the Data Supplement). The adjudicated events included (1) death; (2) cardiac and (3) noncardiac death (in which a direct cause attributable to cardiac disease is not present); (4) hospitalization for HF (in which the primary diagnosis for hospitalization is decompensated HF established as the finding at admission of both of the following conditions listed: (a) dyspnea or respiratory distress or tachypnea at rest or with minimal exertion and (b) evidence of elevated cardiac filling pressure or pulmonary congestion [pulmonary congestion/ edema at physical examination or chest x-ray; plasma BNP levels ≥200 pg/mL; or invasive measurement of LV end-diastolic pressure >18 mm Hg or of pulmonary artery occluding pressure >16 mm Hg]) 20 ; (5) acute myocardial infarction 21 ; (6) acute renal failure (defined as in increase in plasma creatinine levels of 100%); (7) sepsis (or other serious infection requiring antibiotic therapy); and (8) acute stroke.
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Study End Points
The coprimary end points were the placebo-corrected changes in peak Vo 2 or the VE/Vco 2 slope after 2 weeks of treatment, by comparing patients treated with anakinra (pooled anakinra group, n=40) versus placebo (n=20). 8 The rationale for using the 2-week end point as primary end point derives from the improvement in peak Vo 2 after 2 weeks of treatment, documented in 2 pilot trials in stable HF patients. 5, 6 Additional end points included (1) changes in peak Vo 2 or the VE/Vco 2 slope at 4, 12, and 24 weeks in each of the 3 groups; (2) structural and functional parameters at Doppler echocardiography at each follow-up visit in each group to provide mechanistic insight; (3) quality-of-life assessment: the MLWHF and the DASI at 2, 4, 12, and 24 weeks in each of the 3 groups; (4) biomarkers; and (5) clinical outcomes: such as death (cardiac and noncardiac) and rehospitalization for HF or for other causes ≤24 weeks.
Statistical Analysis
Descriptive summaries of continuous measurements are reported as median and interquartile ranges because of potential deviation from gaussian distribution. Descriptive summaries of categorical measurements consist of frequencies, proportions, and 95% confidence intervals, when applicable. All analyses were conducted after database locking on November 12, 2016, and based on the intention-to-treat principle (ie, analyzing groups as randomized and including all patients with outcome data available). The Statistical Package for Social Studies software 22.0 (IBM, New York, NY) was used. The difference in interval changes in peak Vo 2 or the VE/Vco 2 slope at 2 weeks between the pooled anakinra versus placebo groups were compared using random-effect ANOVA for repeated measures to analyze the effects of treatment within each group and the effect of time×group allocation. Unadjusted P values are reported throughout, with statistical significance for the coprimary end points set at the 2-tailed 0.025 level. Cases with missing data for the primary end point were omitted from the analysis. To evaluate the group differences in the secondary end points, data were compared across all groups using the random-effect ANOVA for repeated measures as indicated above for paired analyses or Kaplan-Meier curves with log-rank testing for event rates. Plasma levels of CRP were compared across groups after log10 transformation:
Given an expected average peak Vo 2 of 15±3.5 mL/kg per minute for HF patients, 40 subjects randomized to anakinra and 20 to placebo (2:1 randomization) provided >99%, >99%, 99%, and 86% power to detect a difference in peak Vo 2 of 3.5, 3.0, 2.5, and 2.0 mL/kg per minute.
Considering that the main variable of interest (peak Vo 2 ) is expected not to improve over time with placebo in patients with systolic HF, [23] [24] [25] we chose the last observation carried forward method to impute the missing data at 4, 12, and 24 weeks. Exclusion of patient with missing data would have inevitably lead to a survivorship bias. 26 We also performed the Little's Missing Completely At Random test to determine whether the appropriateness of imputing missing values (Data Supplement) and performed a Multivariate Imputation by Chained Equation 27 to validate the finding of peak Vo 2 using a different method for data inference (Data Supplement).
RESULTS
Screening and Randomization
Screening started on January 23, 2014, and closed on March 23, 2016: 180 patients were assessed and 60 were randomized 1:1:1 to the 3 different groups. Eight patients (13%) were lost to follow-up before the visit 2 at 2 weeks. Of the 52 patients who were enrolled and had at least 1 follow-up visit, 18 (35%) were randomized to placebo for 12 weeks, 16 (30%) to anakinra for 2 weeks, and 18 (35%) to anakinra for 12 weeks (Figure 1) . Fifty patients were uninterested in being screened for CRP or participating in the study but agreed to be followed clinically in an observational arm of the study, without any investigational treatment. Seventy patients were excluded for other reasons listed in Figure 1 .
Characteristics of the Patients
The Table shows a summary of the clinical and demographic characteristics of the patients. Guideline-directed HF therapies at baseline and at the end of the study are shown in the Table and in Table IV in the Data Supplement. With the exception of a lower use of hydralazine/isosorbide in the placebo group at baseline, there were no statistically significant differences between groups. There was a trend toward higher NT-proBNP (N-terminal pro-B-type natriuretic peptide) plasma levels at baseline in the placebo group, although it did not reach statistical significance (P=0.07).
Effects on Peak Aerobic Capacity (Vo 2 ) and Ventilatory Efficiency (VE/Vco 2 Slope)
Respiratory exchange ratio ranged from 1.0 to 1.39 with median values between 1.08 and 1.18, without any significant difference among the 3 groups. When compared with placebo (n=18), treatment with anakinra (n=36, combining 2-week and 12-week treatment) failed to improve peak Vo 2 or the VE/Vco 2 slope at 2 weeks. Figure 2 shows the changes in peak Vo 2 or the VE/Vco 2 slope at 2, 4, 12, and 24 weeks in the 3 dif- ferent groups. No significant changes in peak Vo 2 were seen in the group treated with placebo or with anakinra for 2 weeks. However, treatment with anakinra in the 12-week group was associated with a significant improvement in peak Vo 2 from 14.5 (10.5-16.6) mL/kg per minute at baseline to 15.7 (11.8-17.3) mL/kg per minute at 4 weeks (P=0.005) and to 16.1 (13.2-18.6) mL/kg per minute at 12 weeks (within-group P=0.009; median increase from baseline, 2.1 mL/kg per minute; 95% confidence interval, 0.6-3.6). We validated the statistical significance of the increase in peak Vo 2 from baseline to 12 weeks in the 12-week anakinra group using a multivariate imputation by chained equation instead of the last observation carried forward method for the missing data inference (multivariate P value=0.007). When directly compared, the changes in the peak Vo 2 in the anakinra 12-week treatment group were not significantly different between treatment groups. CRP indicates C-reactive protein; DASI, Duke Activity Status Index; E, early mitral pulsed-wave Doppler flow velocity; E′, early mitral annulus tissue pulsed-wave Doppler velocity; LVEF, left ventricular ejection fraction; MLWHF, Minnesota Living With Heart Failure Questionnaire; NTproBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; OUES, oxygen uptake efficiency slope; VE/Vco 2 slope, minute ventilation-carbon dioxide production slope; and Vo 2 , volume of oxygen production. *The only parameter for which the groups were significantly different at baseline.
Treatment with anakinra for 12 weeks was also associated with a nominal improvement in VE/Vco 2 slope from 34.9 (29.4-41.4) to 31.7 (27.3-34.2; within-group P=0.037) at 12 weeks; however, it did not reaching the predefined statistical significance set at P=0.025. Normalization of the VE/Vco 2 by peak Vo 2 (VE/ Vco 2 :Vo 2 ratio) provides a stronger prognostic indicator than the individual parameters 28 : anakinra for 12 weeks provided a significant improvement (reduction) at 4, 12, and 24 weeks (P=0.005, P=0.002, and P=0.018, respectively), whereas no significant changes were seen with placebo or anakinra 2-week groups ( Figure II in the Data Supplement).
Effects on CRP Plasma Levels
CRP plasma levels were used as a measure of systemic inflammation. Anakinra given for 2 weeks significantly reduced CRP levels, from 7.0 (2.9-14.6) to 1.5 (0.7-4.1) mg/L, in the anakinra-treated patients (n=34) versus from 5.9 (2.2-13.5) to 3.0 (1.8-11.8) mg/L in the placebo (P=0.001 for between-group comparison). Figure 3 shows the changes in plasma CRP at 2, 4, 12, and 24 weeks in the 3 different groups. CRP at 12 weeks was reduced by a median of 66% in the 12-week anakinra group (P=0.011), whereas by 12 weeks, the CRP levels in anakinra 2-week treatment group were no longer significantly different from baseline. Changes in CRP levels at 12 weeks showed a correlation with changes in peak Vo 2 (R=−0.57; P=0.001; Figure III in the Data Supplement).
Doppler Echocardiography
There were no significant changes in LVEF in the placebo group (from 28% [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] at baseline to 28% at 12 weeks). A trend toward improved LVEF was noted in the anakinra-treated groups (from 33% [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] to 43% [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] ; P=0.002 in the 2-week treatment group; and from 32% [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] to 38% [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] ; P=0.18 in the 12-week treatment group; Figure 4 ). The changes in LVEF at 12 weeks showed no significant correlation with changes in peak Vo 2 (R=+0.22; P=0.12). A modest reduction in left ventricular end-diastolic volume during the 12 weeks was noted in all 3 groups without significant differences between groups (data not shown). The E/E′ ratio, an indirect measure of elevated LV filling pressures, was unchanged over time in the placebo group, whereas it showed a trend toward improvement over time in the anakinra-treated groups, with a significant reduction (from 18 [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] to 12 [9] [10] [11] [12] [13] [14] [15] [16] [17] ; P=0.006) at 12 weeks in the anakinra 12-week group (Figure 4) . Treatment with anakinra for 12 weeks improved ventriculo-arterial coupling, E a /E es ratio, and stroke work efficiency, without significant changes in arterial blood pressure or heart rate ( Figure IV 
Quality-of-Life Measures
Patients treated with anakinra for 12 weeks reported a significant improvement in the DASI over time, reflecting an improved perceived functional capacity, whereas those treated with placebo or with anakinra for 2 weeks did not ( Figure 5 ). The improvement in DASI at 12 weeks showed a modest correlation with the improvement in peak Vo 2 (R=0.30; P=0.034), reduction in CRP levels (R=−0.29; P=0.039), and improved E a /E es (R=0.33; P=0.023) and stroke work efficiency (R=0.30; P=0.043). HF symptoms burden measured with as MLWHF scores significantly improved in all 3 treatment groups, although the improvement was numerically greatest in the anakinra groups, and the improvement in MLWHF at 12 weeks also showed a correlation with peak Vo 2 (R=−0.33; P=0.018).
Effects on Cardiac Events
There was 1 death (6%) because of cardiac cause (worsening HF) in the placebo group and 1 death (6%) because of a cardiac cause (acute myocardial infarction) in the anakinra 2-week group (occurring after treatment with anakinra had been completed) and no deaths (0%) in the anakinra 12-week group. For comparison, the 6-month mortality in the observational (noninterventional) arm was 8% (4 of 50 patients; Figure V in the Data Supplement).
The incidence of the composite end point of death because of any cause and readmission for HF was 5 patients (28%) in the placebo group, 5 patients (31%) in the anakinra 2-week treatment group, and 1 patient (6%) in the anakinra 12-week group (log-rank test P=0.10; Figure 6 ). There were a total of 11 HF admissions in the placebo group (1 patient had 4 admissions, 1 patient had 3 admissions, 1 patient had 2 admission, and 2 patients had 1 admission each), 8 HF admissions in the anakinra 2-week treatment group (1 patient had 4 admissions and 4 patients had 1 admission each), and 3 HF admissions in 1 patient in the anakinra 12-week group. The incidence of the combined end point of death and HF hospitalization in the observational arm was 18 (36%; Results section in the Data Supplement; Figure V in the Data Supplement). There was 1 admission for acute myocardial infarction (fatal) in the anakinra 2-week group (6%) and none in the other 2 groups. There were no episodes of unstable angina or urgent revascularization. Two patients in the placebo group (11%) and 1 (6%) in the anakinra 2-week group had an admission prompted by a ventricular or supraventricular arrhythmia (Table VI in 
Noncardiac Adverse Events
Treatment with anakinra was well tolerated, with no serious unanticipated adverse events. Two patients in the placebo group (11%), 1 patient in the anakinra 2-week group (6%), and 1 patient in the anakinra 12-week group (6%) experienced a serious infection requiring prescription of an antimicrobial drug, considered to be unrelated. One patient in each group (6%) experienced an ischemic or hemorrhagic stroke, considered to be unrelated. One patient in the placebo (6%) and 3 patients in the anakinra 2-week group (19%) experienced acute kidney injury (doubling of serum creatinine): all 4 of these patients had complete recovery of renal function by week 24. A complete list of clinical events is available in Table VI in the Data Supplement.
Additional Sensitivity Analyses
The effects of anakinra treatment on NT-proBNP levels and stratifications according to NT-proBNP levels are shown in the Data Supplement and Tables VII and VIII in the Data Supplement. We also stratified patients according to LVEF≤35% (Table IX in the Data Supplement) and use of hydralazine/isosorbide at baseline (Table X in the Data Supplement) to account for potential imbalances in the baseline characteristics. None of these parameters showed a significant interaction with anakinra effect.
DISCUSSION
There is an urgent need to develop novel therapeutic strategies to improve cardiorespiratory fitness, alleviate symptoms, and reduce hospitalizations in patients with recently decompensated HF. Pilot phase II studies of treatment with an IL-1 blocker, anakinra, showed a The incidence of death or readmission for HF at 24 wk was 30% in the placebo group, 31% in the group treated with anakinra for 2 wk, and 6% in the group treated with anakinra 12 wk (log-rank P test P=0.10).
reduction of CRP and improvement in peak Vo 2 in stable ambulatory patients with systolic or diastolic HF 5, 6 and a reduction in CRP within 3 days of treatment with anakinra in patients with acute decompensated systolic HF. 7 The current clinical trial was designed to expand previous findings by treating patients with severe systolic HF who had been admitted with acute HF decompensation and to determine the effects on peak aerobic capacity.
The most robust finding of the current study is that anakinra reduces serum CRP levels in patients with decompensated HF. Although this could be expected considering the preclinical data and the small pilot studies already completed, the effects of shorter and longer treatments may differently affect the inflammatory response. In the current study, anakinra reduced CRP levels early (as measured at the 2-week follow-up) and in a sustained manner (persistent CRP reduction at 12 weeks). This finding deviates from studies using other cytokine inhibitors such as infliximab (a blocker of TNF-α [tumor necrosis factor-α]), in which CRP levels were reduced for 2 weeks but then returned to baseline levels despite continued treatment. 29 Etanercept, another TNF-α blocker, had only a modest effect on the levels of interleukin-6, an inducer of CRP, and no documented effects on CRP levels in HF patients. 30 This divergence of effects is of particular importance because clinical trials with TNF-α blockers have failed to improve clinical outcomes in HF. 29, 31 The effects of anakinra on CRP levels also show that 2 or 12 weeks treatment do not cure systemic inflammation in HF. The serum CRP levels tend to return to baseline within weeks of cessation of therapy. There is, however, no evidence of rebound (to above baseline levels), which is seen with other antiinflammatory drugs (ie, losmapimod 32 ). The current study was designed also to evaluate the effects of shorter (2 weeks) or longer (12 weeks) treatment with anakinra on peak aerobic exercise capacity (peak Vo 2 ) and ventilatory efficiency (the VE/Vco 2 slope). Despite an initial reduction in CRP levels at 2 weeks, anakinra failed to improve peak Vo 2 or VE/Vco 2 slope at 2 weeks. An improvement in both peak Vo 2 , and marginally of the VE/Vco 2 slope, was, however, seen at 4 and 12 weeks within the group of patients that received anakinra for 12 weeks, thus suggesting the need for longer treatment duration to translate in improved exercise capacity and quality-of-life measures. It is important to note, however, that the small number of cases in each group, the multiple group comparisons, the missing data imputation, the potential imbalance in baseline characteristics (ie, NT-proBNP levels), and the lack of statistical significance when directly comparing changes in placebo versus anakinra make it necessary for these findings to be validated in additional studies.
The mechanism(s) by which anakinra improved functional capacity at 12 weeks cannot be ascertained in this study, but a direct effect on the heart is supported by a parallel improvement in ventricular elastance (E es ), ventriculo-arterial coupling (E es /E a ), stroke work efficiency, and diastolic functions (E/E′ ratio). Although any individual surrogate end point and efficacy markers by themselves in phase II may not be sufficient to inform prospects of success in phase III trials, a combination of markers provides better cumulative information to guide downstream research endeavors, 33 and as such, the results seen in the 12-week anakinra group are promising.
Patients with HF who experience a decompensation requiring hospital admission constitute a high-risk group. As expected, we observed a high hospital readmission rate for HF in the overall study population, occurring in ≈30% of placebo-treated patients and patients in the observational arm. The majority of HF readmissions in the placebo or untreated groups occurred within the first 8 weeks. In this pilot study, we sought to determine whether a signal for reduced hospital readmission could be seen with anakinra. The Kaplan-Meier curves show a potential rightward shift for the event-free survival curve for the anakinra 2-week treatment group with the majority of events occurring after week 8 (6 weeks after cessation of anakinra), yet the 6-month event-free survival was the same in this group as in the placebo or untreated group and a promising event-free survival curve for the anakinra 12-week treatment group. Given that the study was not powered to detect differences in readmission rates, these observations should be used only as an estimate of effect size to design appropriately powered future studies.
In conclusion, treatment of patients with recently decompensated HF with anakinra for 12 weeks was well tolerated and associated with an improved peak aerobic capacity, whereas treatment for 2 weeks was not. Further studies are needed to confirm these findings and explore the therapeutic value of IL-1 blockade with anakinra to improve cardiorespiratory fitness and prevent HF rehospitalization in patients with systolic HF. The results of the recently completed CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) showing a significant reduction in composite cardiovascular end point of acute myocardial infarction, stroke, and cardiac death with canakinumab, an antibody blocking IL-1β, in patients with previous myocardial infarction and systemic inflammation supports the concept of a beneficial effect of IL-1 blockade in heart disease. 34, 35 
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